Skip to main content

PET Imaging in Drug Design and Development

Objective

The drug development strategy currently pursued by the pharmaceutical industry worldwide is inefficient and unsustainable for the health care system. To keep the latter affordable, drug development should become more efficient and drug treatment should become more “personalized” and “rationalized”. Molecular imaging can play a pivotal role in changing the landscape of drug design/development and improving the health care system. Positron Emission Tomography (PET) imaging, in particular, is the technology that has the potential to lead this fundamental innovation by providing at a much earlier stage reliable answers to key questions emerging during the care cycle: what and where is the disease? Is the disease accurately targeted by the therapy? Is the treatment effective? By answering the questions above, PET imaging has the capacity to render much more effectively the transition from pre-clinical to clinical phase, and to strongly facilitate the development of better drugs at an earlier stage and in a much more sustainable manner. The main obstacle to this change of paradigm in drug design and development is the lack of suitably trained translational scientists directly involved in PET imaging and imaging scientists with high-profile training in chemistry and PET-radiochemistry, which is particularly dramatic in Europe. This consortium is ideally suited to fill this gap, by providing top-quality training to the next generation of translational PET imaging scientists who will play a key role in shaping the future of drug design and development. The PET3D ETN will focus on 15 cutting-edge research projects in the 3 main therapeutic areas (oncology, cardiovascular, central nervous system) that will be conducted by 15 ESRs at 8 European beneficiary Institutions, 6 academic (all having a PET center on site) and 2 non-academic (one with a PET center on site and one big pharmaceutical company) representing the drug design and development terminus of the project.

Call for proposal

H2020-MSCA-ITN-2015
See other projects for this call

Coordinator

LOUGHBOROUGH UNIVERSITY
Address
Ashby Road
LE11 3TU Loughborough
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 165 187,34

Participants (9)

STICHTING VU

Participation ended

Netherlands
EU contribution
€ 0
Address
De Boelelaan 1105
1081 HV Amsterdam
Activity type
Higher or Secondary Education Establishments
VRIJE UNIVERSITEIT BRUSSEL
Belgium
EU contribution
€ 501 120
Address
Pleinlaan 2
1050 Brussel
Activity type
Higher or Secondary Education Establishments
UNIVERSITETET I BERGEN
Norway
EU contribution
€ 572 550,48
Address
Museplassen 1
5020 Bergen
Activity type
Higher or Secondary Education Establishments
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE
Spain
EU contribution
€ 495 745,92
Address
Paseo Miramon 182, Parque Tecnologico De San Sebastian Edificio Empresarial C
20009 San Sebastian
Activity type
Research Organisations
WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER
Germany
EU contribution
€ 498 432,96
Address
Schlossplatz 2
48149 Muenster
Activity type
Higher or Secondary Education Establishments
IMANOVA LIMITED
United Kingdom
EU contribution
€ 273 287,88
Address
Burlington Danes Building, Imperial College London Hammersmith Hospital, Du Cane Road
W12 0NN London
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ASTRAZENECA AB
Sweden
EU contribution
€ 263 659,32
Address
Vastra Maelarhamnen
151 85 Sodertaelje
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
STICHTING VUMC
Netherlands
EU contribution
€ 510 748,56
Address
De Boelelaan 1117
1081 HV Amsterdam
Activity type
Research Organisations
THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN

Participation ended

United Kingdom
EU contribution
€ 620 515,32
Address
King's College Regent Walk
AB24 3FX Aberdeen
Activity type
Higher or Secondary Education Establishments